Here are relevant reports on : peptide-therapeutics-market
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Peptide Synthesis Market by Instruments (Synthesizers, Purification, Lyophilizers, Analytical), Reagents (Amino Acids, Resins), Technique (Chemical, Biological), Services (Custom Synthesis, Modification), Application, End User - Global Forecast to 2031
The global peptide synthesis market is projected to reach USD 1.54 billion by 2031, growing at a CAGR of 9.5% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
RNAi & Peptide-Based Pesticides Market by Crop Type (Fruits & Vegetables, Cereals & Grains, Oilseed & Pulses, Other Crop Types) And Region (North America, Europe, South America, Rest Of The World) - Global Forecast to 2030
According to MarketsandMarkets, the global market for RNAi-based pesticides is estimated at USD XX million in 2024 and is projected to reach USD XXX.X million by 2030, at a high CAGR of 90%, while the Peptide-based pesticides market is estimated at USD XX.X million in 2024 and is projected to reach USD XXX.X million by 2030, at a double-digit CAGR of 66.8% during the forecast period. The peptide-based pesticides market is dominated by companies such as Vestaron Corporation (US), Innatrix, Inc. (US), Elemental Enzymes (US), Solasta Bio (UK), Micropep (France), Invaio Sciences (US), and Genvor Incorporated (US). As a market pioneer, Vestaron's SPEAR® brand highlights its peptide technology, offering a distinct mode of action compared to traditional synthetic pesticides.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Biosimulation Market by Phase (Drug Discovery, Preclinical, Regulatory), Modality (Antibody, Peptide), Application (Molecular Design, PK/PD, QSP, Trial Simulation, Disease Modeling), Indication (Cardio, Onco), End User (CRO, Pharma) – Global Forecast to 2031
The global biosimulation market is projected to reach USD 9.24 billion by 2031, growing at a CAGR of 16.7% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035
The global Next-generation drug conjugates (NDCs) market is projected to reach USD 42.55 billion by 2035, growing at a CAGR of 11.7% during the forecast period (2026–2035). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Peptide APIs Market By Type (Innovative, Generic), Synthesis Technology (Liquid-Phase, Solid-Phase, Hybrid), Molecule (Semaglutide, Tirzepatide), Application (Metabolic, Endocrine), and End User (Biotechnology Companies, CMOs) – Global Forecast To 2031
Peptide Apis Market
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: November 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
